References
1. Mercurio V, Bianco A, Campi G,
Cuomo A, Diab N, Mancini A, Parrella P, Petretta M, Hassoun PM, Bonaduce
D. New Drugs, Therapeutic Strategies, and Future Direction for the
Treatment of Pulmonary Arterial Hypertension. Curr Med Chem.2019;26(16):2844-2864.
2. Galie N, Humbert M, Vachiery JL,
Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A,
Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and
treatment of pulmonary hypertension: The Joint Task Force for the
Diagnosis and Treatment of Pulmonary Hypertension of the European
Society of Cardiology (ESC) and the European Respiratory Society (ERS):
Endorsed by: Association for European Paediatric and Congenital
Cardiology (AEPC), International Society for Heart and Lung
Transplantation (ISHLT). Eur Respir J. 2015;46(4):903-975.
3. Simonneau G, Gatzoulis MA, Adatia
I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar
R, Landzberg M, Machado RF, et al. Updated clinical classification of
pulmonary hypertension. J Am Coll Cardiol. 2013;62(25
Suppl):D34-41.
4. Simonneau G, Montani D, Celermajer
DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R.
Haemodynamic definitions and updated clinical classification of
pulmonary hypertension. Eur Respir J. 2019;53(1).
5. Pietra GG, Capron F, Stewart S,
Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment
of vasculopathies in pulmonary hypertension. J Am Coll Cardiol.2004;43(12 Suppl S):25S-32S.
6. Leopold JA, Maron BA. Molecular
Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial
Hypertension. Int J Mol Sci. 2016;17(5).
7. Ciuclan L, Bonneau O, Hussey M,
Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G,
et al. A novel murine model of severe pulmonary arterial hypertension.Am J Respir Crit Care Med. 2011;184(10):1171-1182.
8. Ryan JJ, Marsboom G, Archer SL.
Rodent models of group 1 pulmonary hypertension. Handb Exp
Pharmacol. 2013;218:105-149.
9. Ryan J, Bloch K, Archer SL. Rodent
models of pulmonary hypertension: harmonisation with the world health
organisation’s categorisation of human PH. Int J Clin Pract
Suppl. 2011(172):15-34.
10. Sakao S, Tatsumi K. The effects
of antiangiogenic compound SU5416 in a rat model of pulmonary arterial
hypertension. Respiration. 2011;81(3):253-261.
11. Happe CM, de Raaf MA, Rol N,
Schalij I, Vonk-Noordegraaf A, Westerhof N, Voelkel NF, de Man FS,
Bogaard HJ. Pneumonectomy combined with SU5416 induces severe pulmonary
hypertension in rats. Am J Physiol Lung Cell Mol Physiol.2016;310(11):L1088-1097.
12. Tan WSD, Liao W, Zhou S, Mei D,
Wong WF. Targeting the renin-angiotensin system as novel therapeutic
strategy for pulmonary diseases. Curr Opin Pharmacol.2017;40:9-17.
13. Ferreira AJ, Shenoy V, Yamazato
Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP,
Katovich MJ, et al. Evidence for angiotensin-converting enzyme 2 as a
therapeutic target for the prevention of pulmonary hypertension.Am J Respir Crit Care Med. 2009;179(11):1048-1054.
14. Povlsen AL, Grimm D, Wehland M,
Infanger M, Kruger M. The Vasoactive Mas Receptor in Essential
Hypertension. J Clin Med. 2020;9(1).
15. Burrell LM, Johnston CI, Tikellis
C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system.Trends Endocrinol Metab. 2004;15(4):166-169.
16. Velkoska E, Patel SK, Burrell LM.
Angiotensin converting enzyme 2 and diminazene: role in cardiovascular
and blood pressure regulation. Curr Opin Nephrol Hypertens.2016;25(5):384-395.
17. Kulemina LV, Ostrov DA.
Prediction of off-target effects on angiotensin-converting enzyme 2.J Biomol Screen. 2011;16(8):878-885.
18. Shenoy V, Gjymishka A, Jarajapu
YP, Qi Y, Afzal A, Rigatto K, Ferreira AJ, Fraga-Silva RA, Kearns P,
Douglas JY, et al. Diminazene attenuates pulmonary hypertension and
improves angiogenic progenitor cell functions in experimental models.Am J Respir Crit Care Med. 2013;187(6):648-657.
19. Li G, Liu Y, Zhu Y, Liu A, Xu Y,
Li X, Li Z, Su J, Sun L. ACE2 activation confers endothelial protection
and attenuates neointimal lesions in prevention of severe pulmonary
arterial hypertension in rats. Lung. 2013;191(4):327-336.
20. Haga S, Tsuchiya H, Hirai T,
Hamano T, Mimori A, Ishizaka Y. A novel ACE2 activator reduces
monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT
and TGF-beta cascades with restored caveolin-1 expression. Exp
Lung Res. 2015;41(1):21-31.
21. Chen IC, Tan MS, Wu BN, Chai CY,
Yeh JL, Chou SH, Chen IJ, Dai ZK. Statins ameliorate pulmonary
hypertension secondary to left ventricular dysfunction through the
Rho-kinase pathway and NADPH oxidase. Pediatr Pulmonol.2017;52(4):443-457.
22. Dai ZK, Wu BN, Chen IC, Chai CY,
Wu JR, Chou SH, Yeh JL, Chen IJ, Tan MS. Attenuation of pulmonary
hypertension secondary to left ventricular dysfunction in the rat by
Rho-kinase inhibitor fasudil. Pediatr Pulmonol. 2011;46(1):45-59.
23. Faul JL, Nishimura T, Berry GJ,
Benson GV, Pearl RG, Kao PN. Triptolide attenuates pulmonary arterial
hypertension and neointimal formation in rats. Am J Respir Crit
Care Med. 2000;162(6):2252-2258.
24. Nishimura T, Faul JL, Berry GJ,
Vaszar LT, Qiu D, Pearl RG, Kao PN. Simvastatin attenuates smooth muscle
neointimal proliferation and pulmonary hypertension in rats. Am J
Respir Crit Care Med. 2002;166(10):1403-1408.
25. Nishimura T, Vaszar LT, Faul JL,
Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN. Simvastatin
rescues rats from fatal pulmonary hypertension by inducing apoptosis of
neointimal smooth muscle cells. Circulation.2003;108(13):1640-1645.
26. Taraseviciene-Stewart L, Kasahara
Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM.
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes
cell death-dependent pulmonary endothelial cell proliferation and severe
pulmonary hypertension. FASEB J. 2001;15(2):427-438.
27. Folkman J. Angiogenesis research:
from laboratory to clinic. Forum (Genova). 1999;9(3 Suppl
3):59-62.
28. Fong TA, Shawver LK, Sun L, Tang
C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, et al. SU5416
is a potent and selective inhibitor of the vascular endothelial growth
factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis,
tumor vascularization, and growth of multiple tumor types. Cancer
Res. 1999;59(1):99-106.
29. Mendel DB, Laird AD, Smolich BD,
Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver
LK, et al. Development of SU5416, a selective small molecule inhibitor
of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis
agent. Anticancer Drug Des. 2000;15(1):29-41.
30. Al-Merani SA, Brooks DP, Chapman
BJ, Munday KA. The half-lives of angiotensin II, angiotensin II-amide,
angiotensin III, Sar1-Ala8-angiotensin II and renin in the circulatory
system of the rat. J Physiol. 1978;278:471-490.
31. Morrell NW, Atochina EN, Morris
KG, Danilov SM, Stenmark KR. Angiotensin converting enzyme expression is
increased in small pulmonary arteries of rats with hypoxia-induced
pulmonary hypertension. J Clin Invest. 1995;96(4):1823-1833.
32. Guignabert C, de Man F, Lombes M.
ACE2 as therapy for pulmonary arterial hypertension: the good outweighs
the bad. Eur Respir J. 2018;51(6).
33. Tikellis C, Thomas MC.
Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin
Angiotensin System in Health and Disease. Int J Pept.2012;2012:256294.
34. Hanafy S, Tavasoli M, Jamali F.
Inflammation alters angiotensin converting enzymes (ACE and ACE-2)
balance in rat heart. Inflammation. 2011;34(6):609-613.
35. Ferrario CM. ACE2: more of
Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens.2011;20(1):1-6.
36. Dilauro M, Zimpelmann J,
Robertson SJ, Genest D, Burns KD. Effect of ACE2 and angiotensin-(1-7)
in a mouse model of early chronic kidney disease. Am J Physiol
Renal Physiol. 2010;298(6):F1523-1532.
37. Verdecchia P, Cavallini C,
Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and
SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14-20.
38. Chappell MC. The
Angiotensin-(1-7) Axis: Formation and Metabolism Pathways.Angiotensin-(1-7) 2019: 1–26.
39. Eatman D, Wang M, Socci RR,
Thierry-Palmer M, Emmett N, Bayorh MA. Gender differences in the
attenuation of salt-induced hypertension by angiotensin (1-7).Peptides. 2001;22(6):927-933.
40. Almeida AP, Frabregas BC,
Madureira MM, Santos RJ, Campagnole-Santos MJ, Santos RA.
Angiotensin-(1-7) potentiates the coronary vasodilatatory effect of
bradykinin in the isolated rat heart. Braz J Med Biol Res.2000;33(6):709-713.
41. Bader M. ACE2, angiotensin-(1-7),
and Mas: the other side of the coin. Pflugers Arch.2013;465(1):79-85.
42. Zhang C, Zhao YX, Zhang YH, Zhu
L, Deng BP, Zhou ZL, Li SY, Lu XT, Song LL, Lei XM, et al.
Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by
targeting vascular cells. Proc Natl Acad Sci U S A.2010;107(36):15886-15891.